These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16773419)

  • 1. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
    Hussain S; Khayat A; Tolaymat A; Rathore MH
    Pediatr Nephrol; 2006 Jul; 21(7):1034-6. PubMed ID: 16773419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
    Rollot F; Nazal EM; Chauvelot-Moachon L; Kélaïdi C; Daniel N; Saba M; Abad S; Blanche P
    Clin Infect Dis; 2003 Dec; 37(12):e174-6. PubMed ID: 14689363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
    Gupta SK
    AIDS Patient Care STDS; 2008 Feb; 22(2):99-103. PubMed ID: 18260800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.
    D'Ythurbide G; Goujard C; Méchaï F; Blanc A; Charpentier B; Snanoudj R
    Nephrol Dial Transplant; 2007 Dec; 22(12):3656-9. PubMed ID: 17905805
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
    Buchacz K; Young B; Baker RK; Moorman A; Chmiel JS; Wood KC; Brooks JT
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):626-8. PubMed ID: 17133215
    [No Abstract]   [Full Text] [Related]  

  • 7. [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
    Ondounda M; Tanon A; Ehui E; Ouattara I; Kassi A; Aba YT; Aoussi EF; Kakou AR; Eholié SP; Bissagnene E; Kadio A
    Med Mal Infect; 2011 Feb; 41(2):105-7. PubMed ID: 20832214
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction.
    Kapadia J; Shah S; Desai C; Desai M; Patel S; Shah AN; Dikshit RK
    Indian J Pharmacol; 2013; 45(2):191-2. PubMed ID: 23716900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
    Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
    HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
    Atta MG; Fine DM
    AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir-associated decline in renal function.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    J Infect Dis; 2008 Sep; 198(6):937; author reply 937-8. PubMed ID: 18721062
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir].
    Torres Isidro MV; García Benayas T; del Val Gómez Martínez M; González Gallardo F; Gambí Pisonero N; Castilla Miguel S; González-Lahoz J; Gallego Sanz D
    Rev Esp Med Nucl; 2006; 25(2):103-6. PubMed ID: 16759616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir-induced osteomalacia.
    Wanner DP; Tyndall A; Walker UA
    Clin Exp Rheumatol; 2009; 27(6):1001-3. PubMed ID: 20149322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
    González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
    AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
    Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
    AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney damage reported in some tenofovir users.
    TreatmentUpdate; 2003; 15(2):6-7. PubMed ID: 12693362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.